Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceutical Corporation.

Cancer Summaries and Commentaries™: Report from San Diego on Advancements in CAR T-Cell Therapy


Release Date: December 31, 2018
Expiration Date: December 31, 2019
Media: Internet - based

Activity Overview

This online activity is designed to update physicians on data presented at a major oncology meeting, held in San Diego, CA, in December 2018, to facilitate critical assessment and, when appropriate, clinical integration of new evidence. The activity reviews 3 clinically relevant abstracts from the meeting regarding the use of chimeric antigen receptor T-cell (CAR T) therapy in hematologic malignancies. For each abstract, a short summary of key clinical data is accompanied by expert perspective from faculty member Krishna Komanduri, MD, to provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participating

By participating in this exciting program, you will:

  • The rationale of approved and investigational CAR T-cell therapies being explored for the treatment of hematologic malignancies, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma
  • The durability of responses to CAR T-cell therapies
  • The incidence and management of adverse events associated with CAR T-cell therapies

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceutical Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with hematologic malignancies. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with hematologic malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Recognize the unique mechanistic characteristics of CAR T-cell therapy for management of hematologic malignancies, and the role of CAR T-cell therapy in the context of other emerging treatments
  • Review recent clinical trial data for design, safety, and efficacy of CAR T studies in the treatment of hematologic malignancies
  • Apply clinical trial evidence to best practices for patient care in the context of evolving CAR T strategies for hematologic malignancies

Faculty, Staff, and Planners' Disclosures

Faculty

Krishna V. Komanduri, MD
Kalish Family Chair in Stem Cell Transplantation
Professor of Medicine, Microbiology & Immunology
Director, Adult Stem Cell Transplant Program
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL

Disclosures: Ad Hoc Advisor: Kite, Novartis, Juno; Co-Investigator: Kite, Novartis, Adaptimmune, Juno

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By